Sun's Halol Site Faces FDA Action
But Dent In Indian Firm's Business May Be Limited
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
You may also be interested in...
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.
An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.